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VEGFR-3 signaling plays an important role in developmental, physiological, and pathological angiogenesis
and lymphangiogenesis. Tammela et al. in Nature show that VEGFR-3, via Notch regulation, is present on
endothelial tip cells and is critical to sprouting angiogenesis.The production of new blood vessels
during development is an exquisitely reg-
ulated process that results in organ-spe-
cific vascular networks that fulfill required
physiological andmetabolic needs. Ama-
jor mode of new vessel growth is via
sprouting angiogenesis, in which a non-
mitotic tip cell uses filopodia to guide
a sprouting vessel toward an angiogenic
stimulus. The tip cell is followed bymitotic
stalk cells that extend the vessel and
create a lumen capable of transporting
blood. Vascular endothelial growth factor
(VEGF) binds to VEGF receptor (VEGFR)-
2 on tip cells and causes the cells to mi-
grate up a concentration gradient, thus di-
recting new vessel growth. On stalk cells,
VEGF signaling via VEGFR-2 increases
the rate of proliferation, allowing the
sprouting vessel to continue to extend.
Notch signaling, activated by its ligand
Dll4, maintains the appropriate balance
of tip to stalk cells to create proper sprout-
ing and branching patterns in response to
VEGF (Hellstrom et al., 2007). The regula-
tion of sprouting angiogenesis by VEGF
and Notch signaling, however, is also
mediated by other signaling pathways,
including netrins, semaphorins, and, as
shown by Tammela et al. (2008),
VEGFR-3.
Under physiologic conditions, VEGFR-
3 is restricted to lymphatic and some
fenestrated vascular endothelium in the
adult. However, it is upregulated in angio-
genic blood vessels in tumors and
wounds, and blocking VEGFR-3 inhibits
angiogenesis and growth in some tumors
(Laakkonen et al., 2007). During develop-
ment, deletion of VEGFR-3 results in car-
diovascular failure, suggesting a critical
role for VEGFR-3 in blood vessel forma-
tion (Dumont et al., 1998). Additionally,
a blockade of Notch signaling in zebrafish
results in increased angiogenic sprouting178 Developmental Cell 15, August 12, 2008and VEGFR-3 induction (Siekmann and
Lawson, 2007). However, the causal link
between VEGFR-3/Notch signaling and
sprouting angiogenesis was not known
until now. Using a number of genetic and
pharmacologic approaches, Tammela
et al. (2008) reveal that the upregulation
of VEGFR-3 in endothelial tip cells—medi-
ated by the inhibition of Notch—plays
a causal role in sprouting angiogenesis
during early embryonic development, in
postnatal development, and in tumors.
VEGFR-2 is considered the primary
signaling receptor for VEGF during an-
giogenesis. Hence, many antiangiogenic
agents are designed to block the VEGF/
VEGFR-2 pathway in tumors. After initial
response, however, tumors can evade
anti-VEGF/VEGFR-2 treatment by switch-
ing to different molecular pathways (Jain,
2005). Tammela et al. now show that
blocking VEGFR-3 signaling can reduce
the number of vessel branches and endo-
thelial sprouts both during development
and in tumors, resulting in a lower vascu-
lar density. In these models, the authors
find strong expression of VEGFR-3 on
the endothelial tip cells. These tip cells
are also the cells in which the regulation
of VEGFR-3 by Notch is critical for normal
vascular formation, a regulation that may
be lost in some tumors. Tammela et al.
then combine VEGFR-2 with VEGFR-3
blockade and show additive antiangio-
genic and antitumor effects. Moreover,
they show that VEGFR-3 signals can sus-
tain a low level of angiogenesis even in
the presence of VEGFR-2 blockers.
Thus, they propose that a combination
of VEGF/VEGFR-2 and VEGFR-3 block-
ade may improve the outcome of anti-
VEGF therapies.
This proposal raisesmany critical ques-
tions about translating this exciting find-
ing to the clinic: Will such an approachª2008 Elsevier Inc.work for different tumor types? Will this
lead to a durable response in patients?
Finally, how can this dual targeting
approach, which is designed to destroy
tumor vessels, be combined with chemo
and/or radiation therapy, which require
blood vessels for the delivery of drugs
and oxygen (a known sensitizer of radia-
tion and various anticancer drugs)? Ad-
dressing these translational issues is
both necessary and urgent to effectively
use the extensive pipeline of tyrosine ki-
nase inhibitors that target both VEGFR-2
and -3 pathways in various phases of
clinical development (Jain, 2005).
How does tumor-to-tumor variability af-
fect the response to combined VEGFR-2
and -3 blockade? Laakkonen et al.
(2007), showed that different tumors re-
spond to VEGFR-3 blockade to different
degrees, including some tumors that do
not respond at all. Furthermore, emerging
data suggest that VEGFR-3 is expressed
on cancer cells (Su et al., 2008), which
can lead to a direct antitumor effect of
VEGFR-3 blockade, although this remains
controversial. Thus, the responsiveness
of individual tumors to VEGFR-3 blockade
needs to be considered when implement-
ing this therapy.
Can combined VEGFR-2 and -3 block-
ade proposed by Tammela et al. lead to
a durable antiangiogenic response in
patients? In a Phase II trial, glioblastoma
patients responded to cediranib, a
VEGFR-2 and VEGFR-3 tyrosine kinase
inhibitor, for several months, but pro-
gressed eventually in essentially the
same time frame as with bevacizumab
(Avastin), which targets VEGF and has
no direct anti-VEGFR-3 activity (Batchelor
et al., 2007; Norden et al., 2008). Addition-
ally, in animal models, combined VEGFR-
2 and VEGFR-3 blockade with cediranib
did not inhibit established lymphatic
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Previewsmetastasis (Padera et al., 2008). These
data suggest that even combined block-
ade of VEGFR-2 and VEGFR-3 may not
be adequate.
Tammela et al. show that dual target-
ing prunes more vessels than targeting
VEGFR-2 or -3 alone. However, even
with this increased antivascular effect,
the tumors do not regress. Thus, tumor re-
gression and total eradication will require
the addition of drugs and/or radiation
that destroy cancer cells directly. It is in-
teresting to note that blocking VEGFR-2
normalizes the abnormal vessels in skin
adenovirally transduced with VEGF and
VEGF-C, similar to what is seen in some
tumors treated with this same anti-
VEGFR-2 antibody (Jain, 2005). Further-
more, blocking both VEGFR-2 and 3
with antibodies makes these angiogenic
skin vessels look even more normal, like
the control vasculature (Tammela et al.,
2008). So it is probable that dual targeting
will lead to a tumor vasculature more effi-
cient for drug and oxygen delivery, mak-A Descent into the
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tein is critical for transposon silenci
and DNA damage, suggesting that e
for the preservation of germline inte
Sexually reproducing species face the
daunting challenge of transmitting their
genetic material to subsequent genera-
tions without the accumulation of muta-
tions or major genomic alterations. Since
the discovery of transposable elements
(TEs) by Barbara McClintock 60 years
ago, it has been recognized that these
mobile sequences pose a considerable
threat to genomic integrity duringgermlineing these tumors more vulnerable to che-
motherapy and radiation (Jain, 2005). The
challenge will be to identify the optimal
dose and schedule of these agents for
different tumors.
In conclusion, Tammela et al. have
linked the Notch pathway to the produc-
tion of an abnormal tumor vasculature
through the control of VEGFR-3 expres-
sion on endothelial tip cells and its role
in endothelial sprouting. It is important to
test if targeting VEGFR-3 in tumors can
improve the outcome of combined anti-
VEGF/VEGFR-2 and cytotoxic therapies
and lead to longer progression-free and
overall survival.
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DNA methylation is one well-under-
stood mechanism of TE silencing. Re-
cently, a novel transposon-silencing path-
way reliant on small RNAs has attracted
much attention (Aravin et al., 2007). At
the center of this pathway is a class of
small RNAs (termed piRNAs) that bind
thegermline-specific ‘‘Piwi’’ classofArgo-
naute proteins. Many of these piRNAs
are complementary to mobile elements.
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